SE9600791D0 - Method for eradication of Helicobacter pylori infection - Google Patents

Method for eradication of Helicobacter pylori infection

Info

Publication number
SE9600791D0
SE9600791D0 SE9600791A SE9600791A SE9600791D0 SE 9600791 D0 SE9600791 D0 SE 9600791D0 SE 9600791 A SE9600791 A SE 9600791A SE 9600791 A SE9600791 A SE 9600791A SE 9600791 D0 SE9600791 D0 SE 9600791D0
Authority
SE
Sweden
Prior art keywords
drug
helicobacter pylori
eradication
pylori infection
pharmaceutically acceptable
Prior art date
Application number
SE9600791A
Other languages
Swedish (sv)
Other versions
SE9600791L (en
Inventor
Lars Faendriks
Anders Pettersson
Original Assignee
Anders Pettersson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anders Pettersson filed Critical Anders Pettersson
Priority to SE9600791A priority Critical patent/SE9600791L/en
Publication of SE9600791D0 publication Critical patent/SE9600791D0/en
Priority to AU36367/97A priority patent/AU3636797A/en
Priority to PCT/SE1997/001101 priority patent/WO1998057626A1/en
Publication of SE9600791L publication Critical patent/SE9600791L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of L-arginine, at least one of its pharmaceutically acceptable salts or a mixture thereof for production of a drug intended for oral, parenteral, or rectal administration for treatment of infections caused by Helicobacter pylori. The active substance may be included in the drug in its neutral form or as a pro-drug, which is later metabolised by a host into the active form. Furthermore, the drug may include an inert vehicle and/or other pharmaceutically acceptable additives.
SE9600791A 1996-02-27 1996-02-27 Method for eradication of Helicobacter pylori infection SE9600791L (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9600791A SE9600791L (en) 1996-02-27 1996-02-27 Method for eradication of Helicobacter pylori infection
AU36367/97A AU3636797A (en) 1996-02-27 1997-06-19 Use of l-arginine or a pharmaceutically acceptable salt thereof for production of drugs for treatment of (helicobacter pylori) infections
PCT/SE1997/001101 WO1998057626A1 (en) 1996-02-27 1997-06-19 Use of l-arginine or a pharmaceutically acceptable salt thereof for production of drugs for treatment of helicobacter pylori infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600791A SE9600791L (en) 1996-02-27 1996-02-27 Method for eradication of Helicobacter pylori infection
PCT/SE1997/001101 WO1998057626A1 (en) 1996-02-27 1997-06-19 Use of l-arginine or a pharmaceutically acceptable salt thereof for production of drugs for treatment of helicobacter pylori infections

Publications (2)

Publication Number Publication Date
SE9600791D0 true SE9600791D0 (en) 1996-02-27
SE9600791L SE9600791L (en) 1997-08-28

Family

ID=26662529

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600791A SE9600791L (en) 1996-02-27 1996-02-27 Method for eradication of Helicobacter pylori infection

Country Status (3)

Country Link
AU (1) AU3636797A (en)
SE (1) SE9600791L (en)
WO (1) WO1998057626A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507018B2 (en) 1998-03-12 2013-08-13 Mars, Incorporated Products containing polyphenol(s) and L-arginine and methods of use thereof
AU772188B2 (en) 1998-11-17 2004-04-08 Nitromed, Inc. Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
JP4634144B2 (en) 2002-08-01 2011-02-16 ニコックス エスエー Nitrosated proton pump inhibitors, compositions and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07267855A (en) * 1994-03-30 1995-10-17 Taiho Yakuhin Kogyo Kk Glutamine producing agent
EP0689835A3 (en) * 1994-06-30 1996-04-17 Ajinomoto Kk Composition comprising a mixture of amino acids and at least one N-3 fatty acid

Also Published As

Publication number Publication date
AU3636797A (en) 1999-01-04
WO1998057626A1 (en) 1998-12-23
SE9600791L (en) 1997-08-28

Similar Documents

Publication Publication Date Title
WO2002022598A8 (en) Quinolinone derivatives as tyrosine kinase inhibitors
TW332814B (en) Morphinan derivative
EA200200778A1 (en) METHOD OF TREATMENT OR PREVENTION OF HEPATITIS C INFECTION IN THE ORGANISM ORGANISM, PHARMACEUTICAL COMPOSITION AGAINST FLAVIVIRUS, CONNECTION OF FORMULA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION OF EFFECTECH EFFECTURES Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION INEKEKHEKUSA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PROTECTION
CA2039197A1 (en) Pharmaceutic Formulation for the Treatment of Alcoholism
DK0538011T3 (en) Salt compositions comprising lipophilic oligosaccharide antibiotic.
FI870457A0 (en) PHARMACEUTICAL FORM FOR STABILIZATION OF THE INTERFERENCE.
CA2003289A1 (en) Use of trifluoromethylphenyl-tetrahydropyridines for the preparation of pharmaceutical compositions useful for the treatment of anxiety and anxio-depressive disorders
CA2386813A1 (en) Bicyclic imidazo-3-yl amine derivatives substituted on the 6-membered ring
EP0992509A3 (en) Novel macrolide derivatives
RU2000122435A (en) INDOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM
IT1284604B1 (en) CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION CONTAINING NIFEDIPINE AS THE ACTIVE SUBSTANCE
SE9600791D0 (en) Method for eradication of Helicobacter pylori infection
ATE310010T1 (en) 6-0-SUBSTITUTED ERYTHTHROMYCIN COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
MXPA01012936A (en) Pharmaceutical composition containing sibutramine and orlistat.
BR0011666A (en) Optically active pyrrolpyridazine derivative or a pharmaceutically acceptable salt thereof, pharmaceutical composition, use in optically active pyrrolpyridazine derivative, method for treating or preventing disease and, process for synthesizing an optically active pyrrolpyridazine derivative or a pharmaceutically acceptable salt thereof
AU636178B2 (en) 7 (alanylaminothiazol-iminoacetamide) substituted cephalosporin derivatives
WO1990003172A3 (en) Bile acids for treatment of viral infections
HRP20020238A2 (en) 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
DK1181300T3 (en) 6-O-carbamate ketolide derivatives
ATE288269T1 (en) MEDICINAL COMPOSITIONS AND PRODUCTION PROCESS OF ERGO ALKALOID-CONTAINING MEDICINAL COMPOSITIONS WITH DELAYED RELEASE OF ACTIVE INGREDIENTS AND IMPROVED BIOAVAILABILITY
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
DK0985414T3 (en) Drug for the treatment of glaucoma and ischemic retinopathy
AU4831279A (en) New compounds
WO2002089734A3 (en) Method for treatment and prevention of disturbances of the central nervous system associated with an alteration of glutamatergic neurotransmission by administration of 2-aminobenzenesulfonamide derivatives

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9600791-9